How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bladder-muscle-dysfunction-overactive.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bladder muscle dysfunction - overactive — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bladder muscle dysfunction - overactive (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bladder muscle dysfunction - overactive, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Myrbetriq	MIRABEGRON	Apgdi	beta3-Adrenergic Agonist [EPC]	Beta-3 adrenergic receptor	2012-01-01
Toviaz	Fesoterodine Fumarate	Pfizer	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Toviaz	FESOTERODINE	Pfizer	fesoterodine	Muscarinic acetylcholine receptor M2	2008-01-01
Vesicare	SOLIFENACIN	Astellas Pharma	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Sanctura	TROSPIUM	AbbVie	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Detrol	TOLTERODINE	Upjohn	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Ditropan Xl	OXYBUTYNIN	Hisamitsu Pharmaceutical Co., Inc.	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	1975-01-01
Oxytrol	Oxytrol	Jewish General Hospital		Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor
Vesicare	Vesicare	University of California, Irvine		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Bladder muscle dysfunction - overactive
AbbVie · 2 drugs in Bladder muscle dysfunction - overactive
· 2 drugs in Bladder muscle dysfunction - overactive
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in Bladder muscle dysfunction - overactive
Jewish General Hospital · 1 drug in Bladder muscle dysfunction - overactive
University of California, Irvine · 1 drug in Bladder muscle dysfunction - overactive
Upjohn · 1 drug in Bladder muscle dysfunction - overactive
Apgdi · 1 drug in Bladder muscle dysfunction - overactive
Astellas Pharma · 1 drug in Bladder muscle dysfunction - overactive

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bladder muscle dysfunction - overactive:

Cite this brief

Drug Landscape (2026). Bladder muscle dysfunction - overactive — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bladder-muscle-dysfunction-overactive. Accessed 2026-06-10.

Bladder muscle dysfunction - overactive full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing